GlassScriptPhysician profile
Eugene A Tolomeo
NPI 1245257013
$122,705.94
in general payments reported to CMS, 2019-2025
67 companies · $27K in 2025
The $27K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $17K · 2021: $12K · 2022: $19K · 2023: $19K · 2024: $14K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $12K · Consulting Fee: $11K · Travel and Lodging: $10K · Education: $76.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,592.00 |
| Food and Beverage | $12,404.94 |
| Consulting Fee | $11,277.50 |
| Travel and Lodging | $10,265.90 |
| Education | $76.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $28,954.75 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Pfizer INC. | $21,656.17 | 2019-2025 | |
| F. Hoffmann-La Roche Ag | $16,616.57 | 2023 | |
| Genzyme Corporation | $10,419.99 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $9,023.70 | 2022 | |
| Genentech USA, INC. | $7,125.70 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Allergan, INC. | $3,651.83 | 2019-2022 | |
| Emd Serono, INC. | $3,238.35 | 2019-2025 | Mavenclad, Mavenclad |
| Abbvie INC. | $2,942.94 | 2019-2025 | Ubrelvy, Botox, Qulipta |
| Biogen, INC. | $2,154.54 | 2019-2025 | Tysabri, Skyclarys, Vumerity |
| Livanova USA, INC. | $1,608.74 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Sunovion Pharmaceuticals INC. | $1,317.56 | 2019-2022 | |
| Lilly USA, LLC | $1,029.00 | 2019-2025 | Kisunla, Amyvid, Reyvow |
| Amgen INC. | $944.08 | 2019-2025 | Uplizna, Aimovig |
| Lundbeck LLC | $889.40 | 2019-2025 | Vyepti |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Tolomeo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.